Michael Rowley

Overview

Best Publications

• Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection

  Vincenzo Summa;Alessia Petrocchi;Fabio Bonelli;Benedetta Crescenzi

  744
  Citations

• Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.

  Philip Jones;Sergio Altamura;Julia Boueres;Federica Ferrigno

  418
  Citations

• MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants

  Vincenzo Summa;Steven W. Ludmerer;John A. McCauley;Christine Fandozzi

  286
  Citations

• Mechanism of Action and Antiviral Activity of Benzimidazole-Based Allosteric Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase

  Licia Tomei;Sergio Altamura;Linda Bartholomew;Antonino Biroccio

  240
  Citations

• Interdomain Communication in Hepatitis C Virus Polymerase Abolished by Small-Molecule Inhibitors Bound to a Novel Allosteric Site

  Stefania Di Marco;Cinzia Volpari;Licia Tomei;Sergio Altamura

  210
  Citations

• Fluorination of 3-(3-(Piperidin-1-yl)propyl)indoles and 3-(3-(Piperazin-1-yl)propyl)indoles Gives Selective Human 5-HT1D Receptor Ligands with Improved Pharmacokinetic Profiles

  M. B. Van Niel;I. Collins;M. S. Beer;H. B. Broughton

  209
  Citations

• Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.

  Philip Jones;Keith Wilcoxen;Michael Rowley;Carlo Toniatti

  204
  Citations

• Current and novel approaches to the drug treatment of schizophrenia.

  Michael Rowley;Linda J. Bristow;Peter H. Hutson

  203
  Citations

• Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor.

  Steven Harper;John A McCauley;Michael T Rudd;Marco Ferrara

  199
  Citations

• Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists.

  Michael Rowley;Janusz J. Kulagowski;Alan P. Watt;Denise Rathbone

  179
  Citations

• 3'-(Arylmethyl)- and 3'-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones : orally active antagonists of the glycine site on the NMDA receptor

  Kulagowski Jj;Baker R;Curtis Nr;Leeson Pd

  162
  Citations

• 4,5-dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species.

  Vincenzo Summa;Alessia Petrocchi;Victor G. Matassa;Cristina Gardelli

  161
  Citations

• Total synthesis of (+)-ophiobolin C

  Michael Rowley;Masamitsu Tsukamoto;Yoshito Kishi

  156
  Citations

• 3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels

  Ian Collins;Christopher Moyes;William B Davey;Michael Rowley

  155
  Citations

• 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: a potent, selective antagonist at human cloned dopamine D4 receptors.

  Rowley M;Broughton Hb;Collins I;Baker R

  153
  Citations

• 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists.

  M Rowley;D J Hallett;S Goodacre;C Moyes

  146
  Citations

• Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant.

  Ester Muraglia;Olaf D. Kinzel;Ralph Laufer;Michael D. Miller

  128
  Citations

• 3-Acyl-4-hydroxyquinolin-2(1H)-ones. Systemically active anticonvulsants acting by antagonism at the glycine site of the N-methyl-D-aspartate receptor complex.

  Rowley M;Leeson Pd;Stevenson Gi;Moseley Am

  125
  Citations

• Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors.

  Paola Pace;M. Emilia Di Francesco;Cristina Gardelli;Steven Harper

  122
  Citations

• Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase.

  Steven Harper;Salvatore Avolio;Barbara Pacini;Marcello Di Filippo

  121
  Citations